In one meta-analysis including more than 6000 patients with NSCLC, an increased rate of any grade and high-grade IRAEs among patients receiving PD-1 inhibitors compared to those receiving PD-L1 inhibitors was found [12]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.